Moderna Therapeutics

Moderna Therapeutics, a pioneering biotechnology company, was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Bob Langer, and Rohan N. Gupta. The company is headquartered in Cambridge, Massachusetts, and is listed on the NASDAQ under the ticker symbol MRNA. Moderna Therapeutics has established itself as a leader in the development of messenger RNA (mRNA) therapeutics, with a focus on treating a wide range of diseases, including those in the fields of oncology, infectious diseases, and rare genetic disorders. The company's innovative approach has garnered significant attention from investors, including Fidelity Investments, Vanguard Group, and Baillie Gifford.

● History

Moderna Therapeutics was founded in 2010, with initial funding from Flagship Pioneering, a venture capital firm founded by Noubar Afeyan. The company's early development was marked by significant investments from AstraZeneca, Alexandria Real Estate Equities, and Merck & Co.. In 2018, Moderna Therapeutics completed an initial public offering (IPO) on the NASDAQ, raising over $600 million in funding. The company has since established partnerships with numerous organizations, including National Institutes of Health (NIH), Bill and Melinda Gates Foundation, and Coalition for Epidemic Preparedness Innovations (CEPI). Moderna Therapeutics has also collaborated with University of Oxford, Harvard University, and Massachusetts Institute of Technology (MIT) on various research projects.

● Technology

Moderna Therapeutics' core technology revolves around the development of messenger RNA (mRNA) therapeutics, which utilize a novel approach to treat diseases. The company's platform, known as mRNA-1273, uses a proprietary lipid nanoparticle (LNP) delivery system to introduce mRNA into cells, where it is translated into a specific protein. This approach has shown promise in treating a range of diseases, including influenza, HIV, and cancer. Moderna Therapeutics has also developed a range of other technologies, including mRNA-1647 and mRNA-4157, which are being investigated for their potential in treating various diseases. The company's research has been influenced by the work of scientists such as Katalin Karikó, Drew Weissman, and Uğur Şahin, who have made significant contributions to the field of mRNA therapeutics.

● Products

Moderna Therapeutics has a diverse pipeline of products in various stages of development, including mRNA-1273, a vaccine candidate for the prevention of COVID-19. The company has also developed mRNA-1647, a vaccine candidate for the prevention of cytomegalovirus (CMV) infection, and mRNA-4157, a personalized cancer vaccine. Additionally, Moderna Therapeutics is investigating the use of mRNA therapeutics for the treatment of rare genetic disorders, such as methylmalonic acidemia and propionic acidemia. The company's products have been influenced by the work of organizations such as World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and European Medicines Agency (EMA).

● Financials

Moderna Therapeutics has experienced significant financial growth in recent years, with revenues increasing from $13.6 million in 2017 to $60.2 million in 2020. The company has received funding from a range of investors, including Fidelity Investments, Vanguard Group, and Baillie Gifford. Moderna Therapeutics has also established partnerships with numerous organizations, including AstraZeneca, Merck & Co., and Pfizer, which have provided significant funding for the company's research and development activities. The company's financial performance has been influenced by the work of analysts such as those at Goldman Sachs, Morgan Stanley, and J.P. Morgan.

● Partnerships_and_collaborations

Moderna Therapeutics has established partnerships with a range of organizations, including National Institutes of Health (NIH), Bill and Melinda Gates Foundation, and Coalition for Epidemic Preparedness Innovations (CEPI). The company has also collaborated with University of Oxford, Harvard University, and Massachusetts Institute of Technology (MIT) on various research projects. Moderna Therapeutics has partnered with AstraZeneca to develop a range of mRNA-based therapies, and has also established a partnership with Merck & Co. to develop a personalized cancer vaccine. The company's partnerships have been influenced by the work of organizations such as World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and European Medicines Agency (EMA).

● Research_and_development

Moderna Therapeutics has a strong focus on research and development, with a range of programs aimed at developing new mRNA-based therapies. The company's research has been influenced by the work of scientists such as Katalin Karikó, Drew Weissman, and Uğur Şahin, who have made significant contributions to the field of mRNA therapeutics. Moderna Therapeutics has established a range of research collaborations, including partnerships with University of Oxford, Harvard University, and Massachusetts Institute of Technology (MIT). The company's research has also been supported by funding from organizations such as National Institutes of Health (NIH), Bill and Melinda Gates Foundation, and Coalition for Epidemic Preparedness Innovations (CEPI). Moderna Therapeutics has also collaborated with Food and Drug Administration (FDA) and European Medicines Agency (EMA) to advance the development of its mRNA-based therapies.

Category:Biotechnology companies